GlassScriptPhysician profile
Jonathan W Hafner
NPI 1811165608
$1,863.65
in general payments reported to CMS, 2019-2025
22 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $159 · 2021: $228 · 2022: $362 · 2023: $317 · 2024: $168 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $371.03 | 2021-2025 | Nucala |
| Optinose US, INC. | $348.63 | 2019-2025 | |
| Alk-Abello, INC | $180.68 | 2019-2022 | |
| Kaleo, INC. | $174.59 | 2019-2023 | Auvi-Q |
| Genzyme Corporation | $151.41 | 2022-2025 | |
| Stryker Corporation | $109.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $84.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $81.57 | 2021-2024 | Dupixent |
| Medtronic, INC. | $69.79 | 2021-2025 | Stealthstation S8 Platform |
| Aerin Medical INC. | $39.06 | 2019-2023 | |
| Genentech USA, INC. | $35.98 | 2021 | |
| Hikma Pharmaceuticals USA | $35.15 | 2024-2025 | Ryaltris |
| Intersect Ent, INC. | $28.89 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $25.16 | 2025 | Voquezna |
| Smith+Nephew, INC. | $19.76 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.93 | 2022 | |
| Axogen | $18.25 | 2019 | |
| Acclarent, INC | $16.19 | 2023 | Acclarent Aera, Relieva Spinplus, Relieva Scout |
| Cochlear Americas | $14.43 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.19 | 2025 | Xhance |
| Aytu Biopharma, INC. | $13.94 | 2020 | |
| Olympus America INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hafner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.